Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors

Tivozanib is a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. A previous clinical trial in the EU and USA indicated that tivozanib at the maximum tolerated dose of 1.5 mg/day showed an antitumor activity in patients with renal cell carcinoma....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Main Authors: Niwakawa, Masashi, Yamaguchi, Raizo, Onozawa, Yusuke, Yasui, Hirofumi, Taku, Keisei, Naito, Tateaki, Akinaga, Shiro, Boku, Narikazu, Yamamoto, Nobuyuki
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2013
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657128/
https://ncbi.nlm.nih.gov/pubmed/23679664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12197
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares